Basilea Pharmaceutica Ltd. Logo
 

News

 
 
Language
Year
Keyword
 
Friday, April 20. 2018
 
Basel, Switzerland, April 20, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that a broad range of posters and presentations on the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held in Madrid, Spain, from April 21 to 24, 2018.
 
more...
 
Wednesday, April 18. 2018
 

Basel, Switzerland, April 18, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that shareholders approved all proposals of the Board of Directors at today's Annual General Meeting of Shareholders (AGM) for the financial year 2017.The shareholders approved the annual report, the financial statements, and consolidated financial statements for the financial year 2017, and approved the discharge of the members of Basilea's Board of Directors and Management Committee. Shareholders also approved carrying forward the accumulated deficit, and re-elected PricewaterhouseCoopers AG, Basel, as auditors.

 
more...
 
Wednesday, April 18. 2018
 
Basel, Switzerland, April 18, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its license partner Asahi Kasei Pharma Corporation ("Asahi Kasei Pharma") has started enrollment in a clinical phase 3 study with the antifungal isavuconazole for the treatment of deep-seated mycosis, comprised of invasive aspergillosis, chronic pulmonary aspergillosis, mucormycosis and cryptococcosis. The study is part of an abbreviated development program. If the study is successfully completed, Asahi Kasei Pharma plans to proceed with the submission of a marketing authorization application for isavuconazole in Japan.
 
more...
 
Tuesday, April 17. 2018
 
Basel, Switzerland, April 17, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oncology drug candidate ARQ 087 (derazantinib), which targets the fibroblast growth factor receptor (FGFR) family of kinases. The exclusive license is worldwide, excluding the People's Republic of China, Hong Kong, Macau and Taiwan.
 
more...
 
Monday, April 09. 2018
 
Basel, Switzerland, April 09, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Avir Pharma Inc. ("Avir Pharma") has launched Basilea's hospital antibiotic Zevtera® (ceftobiprole) in Canada.
 
more...
 
Tuesday, March 06. 2018
 
  • First launch in Latin America
 
more...
 
Thursday, March 01. 2018
 
Basel, Switzerland, March 01, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea's Management Committee as Chief Corporate Development Officer effective March 01, 2018. He will continue to be responsible for strategic planning, business development & licensing, investor relations and public relations.
 
more...
 
Tuesday, February 27. 2018
 
  • 54% increase in total revenue, amounting to CHF 101.5 million
  • Operating loss reduced by 68% to CHF 14.1 million
  • Cash position as of year-end 2017 increased to CHF 310.7 million
  • License and distribution agreements in 2017 for Cresemba® and Zevtera® cover more than 100 countries with CHF 80 million in upfront payments and up to USD 1.1 billion potential milestone payments
 
more...
 
Friday, February 23. 2018
 
Basel, Switzerland, February 23, 2018   Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has commenced enrollment in the first of its two planned clinical phase 3 registration studies of the antibiotic ceftobiprole. The first study evaluates the safety and efficacy of the antibiotic in the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Basilea expects to begin enrollment in the second phase 3 clinical trial of ceftobiprole in the treatment of adult patients with bacteremia (bloodstream infection) caused by Staphylococcus aureus mid-2018. The two trials are designed to be cross-supportive for a potential U.S. registration and are conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).
 
more...
 
Wednesday, February 21. 2018
 
Basel, Switzerland, February 21, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Chief Executive Officer Ronald Scott will retire after 18 years with the company. Basilea's Board of Directors has appointed David Veitch, currently Basilea's Chief Commercial Officer and member of the Management Committee, to succeed Mr. Scott in the role of Chief Executive Officer effective April 19, 2018.
 
more...
 
more back
Info